INSILICO BIOTECHNOLOGY AG

Their core work

Insilico Biotechnology is a Stuttgart-based SME specialized in computational modeling of biological systems — building digital twins and in silico simulations that predict how cells, tissues, and bioprocesses behave. Their core capability is applying mathematical modeling and artificial intelligence to reduce the need for costly wet-lab experiments in biotechnology and pharmaceutical development. They contribute modeling expertise to larger consortia working on problems ranging from systems biology and synthetic biology to vaccine manufacturing optimization.

What they specialise in

How they've shifted over time

In the early phase (2015-2018), Insilico focused on fundamental systems and synthetic biology, contributing modeling capabilities to training networks like SyMBioSys and SynCrop — largely academic, capacity-building projects. From 2021 onward, they shifted toward applied health challenges, joining Inno4Vac with explicit AI and in vitro modeling roles in vaccine development. This represents a clear move from foundational computational biology toward direct pharmaceutical and health-sector application of their modeling tools.

Insilico is transitioning from academic training networks toward applied pharmaceutical R&D, positioning their modeling platform for health-sector impact — particularly in vaccine manufacturing and AI-assisted drug development.

How they like to work

Insilico never leads consortia — they join as a specialist contributor, either as a participant or third party providing computational modeling services. With 87 unique partners across 18 countries from just 4 projects, they operate within large, diverse consortia rather than small focused teams. This pattern suggests they are a trusted niche provider that larger groups bring in for specific modeling capabilities rather than a project initiator.

Despite being a small SME, Insilico has connected with 87 unique partners across 18 countries through participation in large training networks and research consortia. Their network spans broadly across Europe with no narrow geographic concentration.

What sets them apart

Insilico occupies a specific niche: they are one of few SMEs offering dedicated in silico biological modeling as a service to research consortia. While many computational biology groups sit inside universities, Insilico operates as a private company, which means they bring commercial-grade modeling tools and a product-oriented mindset to academic-heavy projects. For consortium builders, they offer a ready-made computational biology capability without the overhead of building it internally.

Highlights from their portfolio

• Inno4Vac
  Their most recent and strategically significant project — a large-scale vaccine innovation initiative running to 2027, marking their pivot into health-sector AI applications.
• SyMBioSys
  Their largest funded project (EUR 249K) and the most aligned with their core identity — systematic modeling of biological systems in a training network format.